

This article was downloaded by:

On: 25 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Synthesis of A New Ribose Modified Analogue of Cyclic Inosine Diphosphate Ribose

Giorgia Oliviero<sup>a</sup>; Nicola Borbone<sup>a</sup>; Jussara Amato<sup>a</sup>; Stefano D'Errico<sup>a</sup>; Gennaro Piccialli<sup>a</sup>; Michela Varra<sup>a</sup>; Luciano Mayol<sup>a</sup>

<sup>a</sup> Dipartimento di Chimica delle Sostanze Naturali, Università di Napoli "Federico II", Napoli, Italy

**To cite this Article** Oliviero, Giorgia , Borbone, Nicola , Amato, Jussara , D'Errico, Stefano , Piccialli, Gennaro , Varra, Michela and Mayol, Luciano(2007) 'Synthesis of A New Ribose Modified Analogue of Cyclic Inosine Diphosphate Ribose', *Nucleosides, Nucleotides and Nucleic Acids*, 26: 10, 1321 – 1324

**To link to this Article:** DOI: 10.1080/15257770701530699

**URL:** <http://dx.doi.org/10.1080/15257770701530699>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SYNTHESIS OF A NEW RIBOSE MODIFIED ANALOGUE OF CYCLIC INOSINE DIPHOSPHATE RIBOSE

**Giorgia Oliviero, Nicola Borbone, Jussara Amato, Stefano D'Errico, Gennaro Piccialli, Michela Varra, and Luciano Mayol** □ *Dipartimento di Chimica delle Sostanze Naturali, Università di Napoli "Federico II," Napoli, Italy*

□ *A new analogue of cyclic inosine diphosphate ribose (cIDPR), in which the N-1 and N-9 ribosyl moieties were substituted by an alkyl moiety and an hydroxy-alkyl chain, has been synthesized and characterized.*


**Keywords** cADPR; cIDPR; IP3; Ca<sup>2+</sup>

### INTRODUCTION

Cyclic ADP-ribose is an endogenous metabolite synthesized from NAD<sup>+</sup> by ADP-ribosyl cyclase in cells.<sup>[1]</sup> In recent years cADPR has been attracting much attention because of its potent calcium-mobilizing activities as well as for its important role as a potent second messenger in cellular Ca<sup>2+</sup> homeostasis, insulin secretion, and T-lymphocytes activation.<sup>[2,3]</sup> It is also known to mobilize intracellular Ca<sup>2+</sup> more actively than inositol-1,4,5-triphosphate (IP3) by a mechanism completely IP3 independent. Since Ca<sup>2+</sup> ion regulate diverse cell functions, the cADPR signalling pathway may become a valuable target for pharmaceutical intervention.

cADPR is characterized by a very labile *N-1* glycosidic bond which is rapidly hydrolyzed, both enzymatically or not, to give ADP-ribose even in neutral aqueous solution. This biological and chemical instability can hinder the studies on cADPR aimed at elucidating its physiological role. Many nonhydrolyzable mimics of cADPR which retained a similar calcium release profile to that of cADPR are reported.<sup>[4]</sup> Some structural modifications on cADPR adenine moiety make the mimic more potent than its parent—e.g. the 3-deaza-cADPR is 70-fold more potent than cADPR.<sup>[5]</sup> Additional structural modification includes the pyrophosphate


Address correspondence to Giorgia Oliviero, Dipartimento di Chimica delle Sostanze Naturali, Università di Napoli "Federico II" via D. Montesano 49, Napoli I-80131, Italy. E-mail: golivier@unina.it



**FIGURE 1** *N-1* and/or *N-9* modified analogues of cIDPR.

moiety. Cyclic adenosine triphosphate ribose was more potent in inducing  $\text{Ca}^{2+}$  release as compared to cADPR.<sup>[6]</sup> Furthermore, *N-1* deribosylated derivatives of cIDPR (methoxyethyl-8-substituted inosine) are found to be novel membrane permeant cADPR mimics causing the release of  $\text{Ca}^{2+}$  in human Jurkat T-lymphocytes.<sup>[7]</sup> Recently we have proposed the syntheses of several analogues of cIDPR in which the *N-1* or the *N-9* ribosyl moiety has been replaced by an alkyl<sup>[8,9]</sup> or hydroxyalkyl chain<sup>[10]</sup> (products **A–C** Figure 1). To collect more information on the role of the *N-1* and *N-9* ribosyl moieties into  $\text{Ca}^{2+}$  release activity, we synthesized the new cIDPR analogue **8** (Scheme 1) containing a penthyl and an hydroxyalkyl chain at *N-1* and *N-9* hypoxanthine base positions, respectively.

The synthetic strategy adopted for **8** is shown in Scheme 1. The *N-9* acyclic ribose inosine derivative **2** was obtained by reaction of the 2',3'-*O*-isopropylidene-inosine **1** with DIBALH.<sup>[11]</sup> After protection of the alcoholic functions of **2** the *N-1* nitro derivative **4** was obtained in good yield by reacting the diacetyl derivative **3** with ammonium nitrate and trifluoroacetic anhydride.<sup>[12]</sup> The reaction of **4** with 5-amino-pentanol-1-ol furnished the derivative **5** which in turn was converted into the bis-phosphorylated compound **6** (80%) by treatment with *S,S*-diphenylphosphorodithioate (cyclohexylammonium salt) in the presence of 2,4,6-triisopropylbenzen-sulfonylchloride (TPSCl) and tetrazole in pyridine. In this reaction we observed the formation of the corresponding triphosphate derivative in 20% yield. **6** was acetylated at secondary alcoholic function and then treated with silver acetate to remove the phosphate protecting group.<sup>[13]</sup> The obtained product **7** was purified by HPLC (RP18) before the cyclization step which was performed as previously described,<sup>[10]</sup> thus obtaining **8** (10% overall yield starting from **1**), whose structure was confirmed by <sup>1</sup>H-NMR, <sup>31</sup>P-NMR, and MS data. Studies on the biological activity of **8** are currently in progress.



**SCHEME 1** Reagents and conditions: **a**) DIBALH, THF; **b**)  $\text{Ac}_2\text{O}$ , pyridine, r.t.; **c**)  $\text{NH}_4\text{NO}_3$ , TFA,  $\text{CH}_2\text{Cl}_2$ ; **d**) 5-aminopentanol, DMF, r.t. 8 hours; **e**) S,S-diphenylphosphorodithioate, TPSCI, pyridine, r.t., 8 hours; **f**)  $\text{Ac}_2\text{O}$ , AgAc, pyridine/ $\text{H}_2\text{O}$ ; **g**) EDC, NMP, r.t.; 60 hours; **h**) aq.  $\text{HCO}_2\text{H}$ , r.t., 3.5 hours.

## REFERENCES

- Hellmich, M.R.; Stumwasser, F. Purification and characterization of a molluscan egg-specific NADase, a second-messenger enzyme. *Cell. Regul.* **1991**, *2*, 193–202.
- Clapper, D.L.; Walset, T.F.; Dargie, P.J.; Lee, H.C. Pyridine nucleotide metabolites stimulate calcium release from sea urchin egg microsomes desensitized to inositol triphosphate. *J. Biol. Chem.* **1987**, *262*, 9561–9568.
- Shuto, S.; Matsuda, A. Chemistry of cyclic ADP-ribose and its analogs. *Curr. Med. Chem.* **2004**, *11*, 827–845.
- Lee, H.C. Physiological functions of cADPR and NAADP as calcium messengers. *Annu. Rev. Pharmacol. Toxicol.* **2001**, *41*, 317–345.
- Wong, L.; Aarhus, R.; Lee, H.C.; Walseth, T.F. Cyclic 3-deaza-adenosine diphosphoribose: A potent and stable analog of cyclic ADP-ribose. *Biochim. Biophys. Acta* **1999**, *1472*, 555–564.
- Zhang, F.J.; Yamado, S.; Gu, Q.M. Synthesis and characterization of cyclic ATP-ribose: A potent mediator of calcium release. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 1203–1205.
- Gu, X.; Yang, Z.; Zhang, L.; Kunerth, S.; Fliegert, R.; Weber, K.; Guse, A. Synthesis and biological evaluation of novel membrane-permeant cyclic ADP-ribose mimics:  $N^1$ -(5''-O-Phosphorylethoxy)methyl-5'-O-phosphorylinosine 5',5'-cyclicpyrophosphate (cIDPRE) and 8-substituted derivatives. *J. Med. Chem.* **2004**, *47*, 5674–5682.
- Galeone, A.; Mayol, L.; Oliviero, G.; Piccialli, G.; Varra, M. Synthesis of a novel *N-1* carbocyclic, *N-9* butyl analogue of cyclic ADP ribose (cADPR). *Tetrahedron* **2002**, *58*, 363–368.

9. Galeone, A.; Mayol, L.; Oliviero, G.; Piccialli, G.; Varra, M. Synthesis of a new  $N^1$ -pentyl analogue of cyclic inosine diphosphate ribose (cIDPR) as a stable potential mimic of cyclic ADP ribose (cADPR). *Eur. J. Org. Chem.* **2002**, 24, 4234–4238.
10. Oliviero, G.; Amato, J.; Piccialli, G.; Varra, M.; Mayol, L. Synthesis of a new  $N$ -9 ribityl analogue of cyclic inosine diphosphate ribose (cIDPR) as a mimic of cyclic ADP ribose (cADPR). *Nucleosides Nucleotides Nucleic Acids* **2005**, 24, 735–738.
11. Hirota, K.; Monguchi, Y.; Kitade, Y.; Sajiki, H. Ribofuranose-ring cleavage of purine nucleosides with diisobutylaluminum hydride: Convenient method for the preparation of purine acyclonucleosides. *Tetrahedron* **1997**, 53, 16683–16698.
12. Ariza, X.; Bou, V.; Villarasa, J. A new route to  $^{15}\text{N}$ -labeled,  $N$ -alkyl, and  $N$ -amino nucleosides via  $N$ -nitration of uridines and inosines. *J. Am. Chem. Soc.* **1995**, 117, 3665–3673.
13. Sekine, M.; Haoki, K.; Hata, T. Synthesis and properties of  $S,S$ -diaryl thymidine phosphorodithioates. *Bull. Chem. Soc. Jpn.* **1981**, 54, 3815–3827.